Actinogen Medical Limited (ACW.XA)
- PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept, placebo-controlled, parallel group trial with a six-week treatment period and four weeks of follow up.
- PR Newswire
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD). This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites.
- Simply Wall St.
Investors in Actinogen Medical (ASX:ACW) have unfortunately lost 53% over the last year
Actinogen Medical Limited ( ASX:ACW ) shareholders will doubtless be very grateful to see the share price up 50% in the...
